Tag: lyme disease testing market growth

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The Lyme disease testing market has seen remarkable growth in recent years, driven by increasing awareness and advances in diagnostic technology. As the prevalence of tick-borne illnesses continues to rise globally, the demand for accurate and timely Lyme disease testing is expected to grow significantly. Let’s examine the current market status, key growth factors, emerging innovations, and the competitive landscape shaping this important healthcare sector.

Steady Expansion in Lyme Disease Testing Market Size and Future Outlook

The market for Lyme disease testing has experienced strong growth, with its size projected to increase from $10.68 billion in 2025 to $11.67 billion in 2026, representing a compound annual growth rate (CAGR) of 9.3%. This positive momentum during the past years is linked to factors such as the rising incidence of Lyme disease, limited awareness around early diagnosis, continued reliance on traditional serological testing methods, an increase in hospital-based diagnostics, and expanding research efforts focused on tick-borne infections. Looking ahead, the market is expected to expand further, reaching $16.46 billion by 2030 with a CAGR of 9.0%. This sustained growth will be driven by the adoption of AI-assisted diagnostic tools, increased availability of home-testing kits, broader use of multi-disease panels, enhanced government funding for surveillance programs, and the integration of cloud-based laboratory data management systems. Key trends in the forecast period also include the growth of point-of-care testing, home-based Lyme disease diagnostics, rapid test kit adoption, multi-pathogen tick-borne panels, and the development of personalized diagnostic protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

Increasing Prevalence of Tick-Borne Illnesses Fueling Lyme Disease Testing Demand

One of the primary factors propelling the Lyme disease testing market is the growing occurrence of tick-borne illnesses worldwide. These diseases are transmitted to humans through bites from infected ticks, which are commonly found in grassy, wooded, or rural regions. The expansion of tick habitats, largely attributed to climate change, has heightened exposure risks and infection rates among populations. This increased prevalence of tick-borne diseases raises the demand for effective Lyme disease testing, as early detection is crucial for managing and treating infections promptly. For example, in March 2025, the U.S. Centers for Disease Control and Prevention (CDC) reported over 89,000 Lyme disease cases in 2023—a number that highlights the persistent burden of tick-related illnesses and reinforces the need for comprehensive testing solutions.

Detailed Segmentation of the Lyme Disease Testing Market

The Lyme disease testing market is comprehensively segmented to cover various testing types, methods, disease stages, sample types, and end-users. Key test types include serological tests, nucleic acid tests, urine antigen tests, and other emerging test types. Testing methodologies encompass Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), and other cutting-edge technologies. The market also considers disease stages such as early Lyme disease, disseminated Lyme disease, chronic Lyme disease, and asymptomatic detection. Sample types analyzed include blood, urine, cerebrospinal fluid (CSF), and other blood derivatives. End-user categories consist of hospitals and clinics, diagnostic laboratories, home care settings, research institutions, and public health organizations. Further subsegments break down serological tests into ELISA, Western Blot, Immunofluorescence Assay (IFA), and Line Immunoassay (LIA); nucleic acid tests into PCR, Loop-Mediated Isothermal Amplification (LAMP), and Next-Generation Sequencing (NGS); urine antigen tests into lateral flow assay, enzyme immunoassay (EIA), and immunoblot urine tests; and other tests including culture-based assays, tick-borne co-infection panels, and AI-assisted diagnostic tools.

Access The Complete Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Innovative Diagnostic Technologies Shaping the Lyme Disease Testing Market

Leading players in the Lyme disease testing industry are heavily investing in the development of advanced diagnostic tools aimed at improving test accuracy, reducing response times, and enabling early detection of the disease. These diagnostic technologies identify specific antibodies, antigens, or genetic material related to the Borrelia burgdorferi bacteria, the causative agent of Lyme disease. For example, in August 2024, UK-based biotechnology firm EpitogenX Ltd. introduced a state-of-the-art Lyme Disease Diagnostic Kit utilizing their proprietary EpitoGen platform. This ELISA-based assay features approximately 120 distinct Borrelia epitopes, providing high sensitivity and specificity for strain-specific detection. Designed for research use, it supports customization for various laboratory settings, enhancing detection precision and enabling deeper understanding of Lyme disease.

Recognized Industry Leaders in the Lyme Disease Testing Market

The competitive environment of the Lyme disease testing market includes several prominent companies such as Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., and Seegene Inc. These organizations are actively advancing diagnostic technologies and expanding service offerings to meet growing market demand.

Geographical Distribution and Growth Patterns in the Lyme Disease Testing Market

In 2025, North America held the largest share of the Lyme disease testing market, driven by robust healthcare infrastructure and high disease prevalence. Meanwhile, the Asia-Pacific region is anticipated to register the fastest growth during the forecast period due to rising awareness, expanding healthcare access, and increasing government initiatives focused on infectious disease monitoring. The market study encompasses key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive view of the global Lyme disease testing landscape.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Lyme Disease Testing Market During The 2026–2030 Period?

The lyme disease testing market has experienced substantial growth in recent years. It is anticipated to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. This historic expansion has been driven by factors such as the rising incidence of lyme disease, limited awareness regarding early diagnosis, reliance on conventional serological testing, increasing hospital-based diagnostics, and growing research in tick-borne diseases.

The lyme disease testing market size is projected to experience robust expansion over the coming years. It will grow to $16.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. This anticipated growth during the forecast period is due to factors such as the embrace of AI-assisted diagnostic tools, an increase in the availability of home-testing kits, the development of multi-disease panels, enhanced government financial support for monitoring tick-borne diseases, and the incorporation of cloud-based laboratory data management systems. Key developments expected throughout this period encompass the broadening of point-of-care testing, the rise of home-based lyme disease diagnostics, the introduction of multi-pathogen panels for tick-borne illnesses, the wider use of rapid test kits, and the implementation of customized diagnostic procedures.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

What Important Drivers Are Powering The Lyme Disease Testing Market Growth?

The increasing occurrence of tick-borne illnesses is anticipated to boost the expansion of the lyme disease testing market in the future. These illnesses encompass various conditions passed to people via bites from contaminated ticks, which are tiny, blood-sucking parasites inhabiting grassy, forested, or countryside environments. An increasing need for treatments for tick-borne illnesses stems from ticks’ broadening geographical distribution due to climate change, resulting in increased exposure and infection levels. As the main way Lyme disease is transmitted, tick-borne illnesses drive the need for Lyme disease testing, making early identification and diagnosis crucial for managing the growing number of infections efficiently. For example, the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated in March 2025 that more than 89,000 Lyme disease cases were reported in 2023, showing a persistently high impact from tick-borne illnesses compared to prior years. Consequently, the growing frequency of tick-borne illnesses is stimulating the expansion of the lyme disease testing market.

Which Segment Divisions Form The Structure Of The Lyme Disease Testing Market?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

What Trends Are Affecting The Growth Of The Lyme Disease Testing Market?

Companies operating in the Lyme disease testing market are increasingly concentrating on technological improvements in diagnostic instruments to boost test precision, decrease processing times, and facilitate the early identification of the condition. Diagnostic tools refer to medical equipment, kits, or technologies utilized to confirm the presence of Lyme disease by identifying distinct antibodies, antigens, or genetic material linked to the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, revealed the launch of a sophisticated Lyme Disease Diagnostic Kit. This kit is an ELISA-based assay engineered using their proprietary EpitoGen platform. It incorporates ~120 distinct Borrelia epitopes, offering high specificity and sensitivity, and is specifically designed for research use (RUO). It supports early, strain-specific detection and can be customized for various laboratory applications. Created for both research and diagnostic labs, it is optimal for enhancing detection accuracy and enabling deeper insights into Lyme disease.

Which Firms Are Competing In The Lyme Disease Testing Market?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Access The Complete Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Region Leads The Lyme Disease Testing Market By Size?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Lyme Disease Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Lyme Disease Testing Market Between 2026 And 2030?

The lyme disease testing market size has experienced robust growth in recent years. It is projected to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The historic increase in this market can be attributed to the rising incidence of lyme disease, limited awareness concerning early diagnosis, reliance on conventional serological testing methods, the increasing prevalence of hospital-based diagnostics, and growing research efforts in tick-borne diseases.

The lyme disease testing market size is anticipated to experience robust expansion over the coming years. This market is projected to reach a value of $16.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. The projected increase during this period is driven by factors such as the integration of AI-assisted diagnostics, the rise in popularity of home-testing kits, the development of multi-disease panels, increased government investment in tick-borne disease monitoring, and the adoption of cloud-based laboratory data management. Key developments expected during the forecast timeframe encompass the wider deployment of point-of-care testing, the availability of home-based lyme disease diagnostics, the emergence of multi-pathogen tick-borne panels, the increased use of rapid test kits, and the implementation of personalized diagnostic protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Strong Drivers Are Impacting The Lyme Disease Testing Market Growth?

The increasing incidence of tick-borne diseases is projected to boost the expansion of the lyme disease testing market moving forward. These illnesses are a category of diseases spread to humans via bites from infected ticks, which are tiny, blood-consuming parasites typically found in grassy, forested, or countryside environments. The growing need for treatments for tick-borne illnesses stems from the widening geographical distribution of ticks due to climate change, resulting in increased exposure and infection rates. As the main method of transmitting Lyme disease, tick-borne illnesses drive the demand for Lyme disease testing, making early detection and diagnosis crucial for effectively handling the increasing number of infection cases. For example, reports from March 2025 by the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated that in 2023, over 89,000 cases of Lyme disease were recorded. This highlights a persistent significant impact from tick-borne illnesses compared to earlier years. Consequently, the escalating occurrence of tick-borne illnesses is propelling the expansion of the lyme disease testing market.

Which Segment Classifications Are Used In The Lyme Disease Testing Market Segment Analysis?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

Which Trends Are Contributing To Changes In The Lyme Disease Testing Market?

Major companies operating in the Lyme disease testing market are concentrating on technological advancements in diagnostic instruments to enhance test precision, reduce processing times, and enable the identification of the disease in its early stages. Diagnostic tools refer to medical devices, kits, or technologies utilized to confirm the presence of Lyme disease by identifying specific antibodies, antigens, or genetic material associated with the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, disclosed the introduction of an advanced Lyme Disease Diagnostic Kit. This is an ELISA-based assay engineered using their proprietary EpitoGen platform. It incorporates approximately ~120 distinct Borrelia epitopes, providing high specificity and sensitivity, and is designated for research use (RUO). It facilitates early, strain-specific detection and can be customized for various laboratory applications. Created for research and diagnostic laboratories, it is optimal for improving detection accuracy and allowing deeper insights into Lyme disease.

Which Firms Are Contributing To The Lyme Disease Testing Market Ecosystem?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Get The Full Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Geographic Region Dominates The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lyme Disease Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Lyme Disease Testing Market Between 2026 And 2030?

The lyme disease testing market size has experienced robust growth in recent years. It is projected to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The historic increase in this market can be attributed to the rising incidence of lyme disease, limited awareness concerning early diagnosis, reliance on conventional serological testing methods, the increasing prevalence of hospital-based diagnostics, and growing research efforts in tick-borne diseases.

The lyme disease testing market size is anticipated to experience robust expansion over the coming years. This market is projected to reach a value of $16.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. The projected increase during this period is driven by factors such as the integration of AI-assisted diagnostics, the rise in popularity of home-testing kits, the development of multi-disease panels, increased government investment in tick-borne disease monitoring, and the adoption of cloud-based laboratory data management. Key developments expected during the forecast timeframe encompass the wider deployment of point-of-care testing, the availability of home-based lyme disease diagnostics, the emergence of multi-pathogen tick-borne panels, the increased use of rapid test kits, and the implementation of personalized diagnostic protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Strong Drivers Are Impacting The Lyme Disease Testing Market Growth?

The increasing incidence of tick-borne diseases is projected to boost the expansion of the lyme disease testing market moving forward. These illnesses are a category of diseases spread to humans via bites from infected ticks, which are tiny, blood-consuming parasites typically found in grassy, forested, or countryside environments. The growing need for treatments for tick-borne illnesses stems from the widening geographical distribution of ticks due to climate change, resulting in increased exposure and infection rates. As the main method of transmitting Lyme disease, tick-borne illnesses drive the demand for Lyme disease testing, making early detection and diagnosis crucial for effectively handling the increasing number of infection cases. For example, reports from March 2025 by the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated that in 2023, over 89,000 cases of Lyme disease were recorded. This highlights a persistent significant impact from tick-borne illnesses compared to earlier years. Consequently, the escalating occurrence of tick-borne illnesses is propelling the expansion of the lyme disease testing market.

Which Segment Classifications Are Used In The Lyme Disease Testing Market Segment Analysis?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

Which Trends Are Contributing To Changes In The Lyme Disease Testing Market?

Major companies operating in the Lyme disease testing market are concentrating on technological advancements in diagnostic instruments to enhance test precision, reduce processing times, and enable the identification of the disease in its early stages. Diagnostic tools refer to medical devices, kits, or technologies utilized to confirm the presence of Lyme disease by identifying specific antibodies, antigens, or genetic material associated with the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, disclosed the introduction of an advanced Lyme Disease Diagnostic Kit. This is an ELISA-based assay engineered using their proprietary EpitoGen platform. It incorporates approximately ~120 distinct Borrelia epitopes, providing high specificity and sensitivity, and is designated for research use (RUO). It facilitates early, strain-specific detection and can be customized for various laboratory applications. Created for research and diagnostic laboratories, it is optimal for improving detection accuracy and allowing deeper insights into Lyme disease.

Which Firms Are Contributing To The Lyme Disease Testing Market Ecosystem?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Get The Full Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Geographic Region Dominates The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lyme Disease Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Lyme Disease Testing Market Between 2026 And 2030?

The lyme disease testing market size has experienced robust growth in recent years. It is projected to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The historic increase in this market can be attributed to the rising incidence of lyme disease, limited awareness concerning early diagnosis, reliance on conventional serological testing methods, the increasing prevalence of hospital-based diagnostics, and growing research efforts in tick-borne diseases.

The lyme disease testing market size is anticipated to experience robust expansion over the coming years. This market is projected to reach a value of $16.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. The projected increase during this period is driven by factors such as the integration of AI-assisted diagnostics, the rise in popularity of home-testing kits, the development of multi-disease panels, increased government investment in tick-borne disease monitoring, and the adoption of cloud-based laboratory data management. Key developments expected during the forecast timeframe encompass the wider deployment of point-of-care testing, the availability of home-based lyme disease diagnostics, the emergence of multi-pathogen tick-borne panels, the increased use of rapid test kits, and the implementation of personalized diagnostic protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Strong Drivers Are Impacting The Lyme Disease Testing Market Growth?

The increasing incidence of tick-borne diseases is projected to boost the expansion of the lyme disease testing market moving forward. These illnesses are a category of diseases spread to humans via bites from infected ticks, which are tiny, blood-consuming parasites typically found in grassy, forested, or countryside environments. The growing need for treatments for tick-borne illnesses stems from the widening geographical distribution of ticks due to climate change, resulting in increased exposure and infection rates. As the main method of transmitting Lyme disease, tick-borne illnesses drive the demand for Lyme disease testing, making early detection and diagnosis crucial for effectively handling the increasing number of infection cases. For example, reports from March 2025 by the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated that in 2023, over 89,000 cases of Lyme disease were recorded. This highlights a persistent significant impact from tick-borne illnesses compared to earlier years. Consequently, the escalating occurrence of tick-borne illnesses is propelling the expansion of the lyme disease testing market.

Which Segment Classifications Are Used In The Lyme Disease Testing Market Segment Analysis?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

Which Trends Are Contributing To Changes In The Lyme Disease Testing Market?

Major companies operating in the Lyme disease testing market are concentrating on technological advancements in diagnostic instruments to enhance test precision, reduce processing times, and enable the identification of the disease in its early stages. Diagnostic tools refer to medical devices, kits, or technologies utilized to confirm the presence of Lyme disease by identifying specific antibodies, antigens, or genetic material associated with the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, disclosed the introduction of an advanced Lyme Disease Diagnostic Kit. This is an ELISA-based assay engineered using their proprietary EpitoGen platform. It incorporates approximately ~120 distinct Borrelia epitopes, providing high specificity and sensitivity, and is designated for research use (RUO). It facilitates early, strain-specific detection and can be customized for various laboratory applications. Created for research and diagnostic laboratories, it is optimal for improving detection accuracy and allowing deeper insights into Lyme disease.

Which Firms Are Contributing To The Lyme Disease Testing Market Ecosystem?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Get The Full Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Geographic Region Dominates The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lyme Disease Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Lyme Disease Testing Market Over The Period 2026–2030?

The market size for lyme disease testing has shown significant growth over recent years. It is anticipated to increase from $10.68 billion in 2025 to $11.67 billion in 2026, registering a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be linked to several factors, including the rising occurrence of lyme disease, inadequate public knowledge concerning early detection, a reliance on conventional serological tests, an uptick in hospital-based diagnostic services, and expanding research into tick-borne illnesses.

The Lyme disease testing market is projected to experience substantial expansion over the coming years. Its size is anticipated to reach $16.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period is fueled by factors such as the integration of AI-assisted diagnostics, the rise of home-testing kits, the development of multi-disease panels, increased government investment in tick-borne disease monitoring, and the adoption of cloud-based laboratory data management systems. Key developments expected during this period include the wider availability of point-of-care testing, the proliferation of home-based Lyme disease diagnostics, the emergence of multi-pathogen tick-borne panels, the increased use of rapid test kits, and the implementation of personalized diagnostic protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

Which Economic Or Industry Drivers Are Impacting The Lyme Disease Testing Market?

An increasing occurrence of tick-borne diseases is projected to drive the expansion of the lyme disease testing market in the future. These conditions encompass various diseases passed to humans via the bite of infected ticks, which are minute, blood-sucking parasites common in grassy, wooded, and rural environments. The growing need for treatments for these illnesses is intensified by the broader distribution of ticks due to climate change, resulting in increased exposure and rates of infection. As the main way Lyme disease is transmitted, tick-borne illnesses boost the demand for lyme disease testing, making early identification and diagnosis crucial for managing the increasing number of infection cases. For example, data from March 2025 by the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency in the U.S., showed that in 2023, more than 89,000 cases of Lyme disease were documented, indicating an ongoing significant impact of tick-borne illnesses when contrasted with prior years. Consequently, the increasing occurrence of tick-borne illnesses is a key factor propelling the expansion of the lyme disease testing market.

How Is The Lyme Disease Testing Market Divided Into Its Major Segments?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

How Are Trends Transforming The Lyme Disease Testing Market Landscape?

Companies prominently involved in the Lyme disease testing market are prioritizing technological enhancements in diagnostic tools to boost test accuracy, shorten turnaround times, and allow for early disease detection. Diagnostic tools include medical devices, kits, or technologies employed to identify Lyme disease by locating specific antibodies, antigens, or genetic material connected to the Borrelia burgdorferi bacteria. As an illustration, in August 2024, EpitogenX Ltd., a biotechnology company from the UK, declared the release of an innovative Lyme Disease Diagnostic Kit. This is an ELISA-based assay created using their unique EpitoGen platform. It contains ~120 different Borrelia epitopes, delivering high specificity and sensitivity, and is designed for research use (RUO). The kit facilitates early, strain-specific detection and can be modified for various laboratory applications. Being developed for both research and diagnostic laboratories, it is well-suited for improving detection precision and yielding greater insights into Lyme disease.

Who Are The Prominent Organizations Shaping The Lyme Disease Testing Market?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Read the full lyme disease testing market report here:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

What Are The Top-Performing Regions Within The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lyme Disease Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25817&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Lyme Disease Testing Market between 2026 and 2030?

The lyme disease testing market has demonstrated robust growth in its size over recent years. It is projected to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. This expansion during the preceding period can be attributed to factors such as an increasing occurrence of lyme disease, insufficient public knowledge about early detection, the continued use of conventional serological testing, a rise in hospital-based diagnostic services, and expanding research initiatives focused on tick-borne diseases.

Significant expansion is anticipated for the lyme disease testing market in the coming years. By 2030, this market is projected to reach $16.46 billion, exhibiting a compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period is propelled by factors such as the implementation of AI-assisted diagnostic tools, the rise in popularity of home-testing kits, the development of multi-disease panels, augmented government funding for surveillance of tick-borne diseases, and the incorporation of cloud-based laboratory data management systems. Key developments expected in this period encompass the broadening of point-of-care testing, the emergence of home-based lyme disease diagnostic solutions, the use of multi-pathogen tick-borne panels, wider acceptance of rapid test kits, and the creation of personalized diagnostic protocols.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

Which Drivers Are Expected To Impact The Lyme Disease Testing Market During The Forecast Period?

The increasing occurrence of tick-borne diseases is anticipated to drive the expansion of the lyme disease testing market in the future. These illnesses represent a category of conditions transmitted to people by the bite of infected ticks, which are tiny, blood-feeding parasites present in grassy, wooded, or rural environments. The escalating need for treatments for tick-borne ailments is further exacerbated by the widening geographical spread of ticks, a consequence of climate change, resulting in increased human exposure and infection rates. As the main method of transmitting Lyme disease, tick-borne illnesses significantly contribute to the need for Lyme disease testing, making early detection and diagnosis essential for effectively managing the growing number of infection cases. For example, the U.S. Centers for Disease Control and Prevention (CDC), a U.S.-based federal public health agency, reported in March 2025 that over 89,000 cases of Lyme disease occurred in 2023, signifying an ongoing substantial impact of tick-borne illnesses relative to prior years. Consequently, the growing prevalence of tick-borne diseases is propelling the expansion of the lyme disease testing market.

Which Segments Are Driving Activity In The Lyme Disease Testing Market?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

What Trends Are Reshaping The Dynamics Of The Lyme Disease Testing Market?

Major companies operating in the Lyme disease testing market are prioritizing technological advancements in diagnostic tools to improve test accuracy, reduce turnaround times, and allow for earlier detection of the disease. Diagnostic tools refer to medical devices, kits, or technologies utilized to identify the presence of Lyme disease by pinpointing specific antibodies, antigens, or genetic material associated with the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, announced the release of a state-of-the-art Lyme Disease Diagnostic Kit. This kit is an ELISA-based assay developed using their proprietary EpitoGen platform. It features approximately 120 distinct Borrelia epitopes, ensuring high specificity and sensitivity, and is specifically designed for research use (RUO). The kit supports early, strain-specific detection and can be customized for various laboratory applications. Intended for research and diagnostic labs, it is ideal for boosting detection accuracy and enabling deeper insights into Lyme disease.

Which Major Firms Are Strengthening Their Position In The Lyme Disease Testing Market?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lyme Disease Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25817&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Lyme Disease Testing Market?

The lyme disease testing market has experienced significant expansion in recent years. Its valuation is expected to climb from $9.77 billion in 2024 to $10.68 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historic growth can be linked to an elevated demand for prompt disease identification, the increasing accessibility of sophisticated diagnostic technologies, a surge in tick populations attributed to climate change, increased government expenditure for controlling vector-borne illnesses, and the advancement of healthcare infrastructure in rural and affected areas.

The lyme disease testing market is projected to experience substantial growth in the coming years. It is anticipated to expand to $15.11 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion during the forecast period is driven by factors such as increased travel to endemic areas, broader adoption of multiplex diagnostic technologies, a surge in outdoor recreational pursuits, rising demand for home-based testing kits, and heightened apprehension regarding co-infections with other tick-borne illnesses. Significant trends expected in the forecast timeframe include progress in molecular diagnostic techniques, advancements in biomarker research, innovation in point-of-care testing devices, evolution in lab-on-a-chip (microfluidic) technology, and improvements in immunoassay technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

What Are The Drivers Pushing New Developments In The Lyme Disease Testing Market?

The escalating occurrence of tick-borne illnesses is anticipated to fuel the expansion of the lyme disease testing market. These illnesses encompass a range of diseases transmitted to humans via bites from infected ticks, which are small, blood-feeding parasites prevalent in grassy, wooded, or rural environments. The growing need for tick-borne illness treatments is largely propelled by climate change, which has broadened the geographic spread of ticks, consequently raising human exposure and infection rates. Since tick-borne illnesses are the primary means of contracting Lyme disease, there is a vital need for early detection and diagnosis to effectively manage the increasing number of infection cases, thereby boosting demand for testing. For instance, according to the Centers for Disease Control and Prevention, a US-based federal public health agency, 71,346 cases of tick-borne disease were reported in 2022 as of July 2024, marking an increase from 36,177 cases in 2021. Consequently, the rising prevalence of tick-borne illnesses is a significant driver for the growth of the lyme disease testing market.

What Are The Different Segment Classifications Within The Lyme Disease Testing Market?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

What Trends Are Expected To Drive The Lyme Disease Testing Market?

Leading companies in the Lyme disease testing market are prioritizing technological innovations in diagnostic instruments to improve test accuracy, shorten turnaround times, and facilitate early detection of the condition. These diagnostic instruments include medical devices, kits, or technologies utilized to identify Lyme disease by detecting specific antibodies, antigens, or genetic material related to the Borrelia burgdorferi bacteria. For example, in August 2024, EpitogenX Ltd., a UK-based biotechnology firm, revealed the introduction of an advanced Lyme Disease Diagnostic Kit. This kit is an ELISA-based assay created using their proprietary EpitoGen platform, featuring approximately 120 distinct Borrelia epitopes, which provides high specificity and sensitivity, and is designed for research use only (RUO). It supports early, strain-specific detection and can be customized for various laboratory applications. Tailored for research and diagnostic labs, it is optimal for enhancing detection precision and fostering more comprehensive insights into Lyme disease.

Which Key Players Are Driving Competition In The Lyme Disease Testing Market?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Everlywell, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Novatein Biosciences, Lyme Diagnostics Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Lyme Disease Testing Market?

North America was the largest region in the lyme disease testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25817&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2025, By The Business Research Company

Infectious Disease Diagnostics Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Biologics Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Lyme Disease Testing Market Evolve in Terms of Growth and Size by 2029?

There has been substantial growth in the market size for Lyme disease testing in the past few years. The market is projected to increase from $9.77 billion in 2024 to $10.68 billion in 2025, representing a compound annual growth rate (CAGR) of 9.3%. Factors contributing to the growth during the historic period include an escalating demand for early detection of diseases, an increase in the availability of sophisticated diagnostic tools, a surge in tick populations due to changes in climate, an increase in government funding directed towards controlling vector-borne diseases, and an expansion in healthcare infrastructure in both rural areas and endemic regions.

The market size for testing lyme disease is anticipated to witness substantial expansion in the upcoming years, with projections indicating a growth to $15.11 billion by 2029, at a compound annual growth rate (CAGR) of 9.1%. This predicted growth during the forecasted period can be credited to a surge in travel to regions where the disease is prevalent, increased application of multiplex diagnostic technologies, a growing trend of outdoor recreational activities, a heightened demand for home-testing kits and an escalation in concerns related to co-infections from other tick-borne diseases. Key market trends projected for the forecast period encompass advances in molecular diagnostic techniques, breakthroughs in biomarker research, innovative technology in point-of-care testing devices, progress in lab-on-a-chip (microfluidic) technology, and improvements in immunoassay technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

What factors are expected to fuel Lyme Disease Testing market growth in the coming years?

The lyme disease testing market is anticipated to grow owing to the increasing occurrence of tick-borne diseases. These diseases, spread to humans through bites from ticks, tiny parasites that thrive in grassy, remote, or forested areas, cause a surge in Lyme disease testing. Climate change, exacerbating the geographic spread of ticks, results in increased exposure and infection rates, fueling the demand for tick-borne illness treatments. Tick-borne illnesses, being the principal transmission method for Lyme disease, necessitate timely detection and diagnosis to efficiently manage the escalating infection cases. As an illustration, the Centers for Disease Control and Prevention, a federal public health agency based in the US, reported 71,346 cases of tick-borne disease in July 2024, a significant increase from 36,177 cases in 2021. Consequently, the growing incidence of tick-borne diseases is stimulating the expansion of the lyme disease testing market.

What Are The Key Findings From The Segmentation Analysis Of The Lyme Disease Testing Market?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

Which Trends Are Expected To Shape The Future Of The Lyme Disease Testing Market?

A significant focus for leading companies in the Lyme disease testing market is the progression of innovative diagnostic tools. Their aim is to enhance the precision of tests, streamline the process, and facilitate early detection of the illness. Diagnostic tools encompass various medical devices, kits, or innovative technologies that can detect Lyme disease by identifying specific antibodies, antigens, or the genetic presence related to Borrelia burgdorferi bacteria. To illustrate, EpitogenX Ltd, a biotech company based in the UK, unveiled a state-of-the-art Lyme Disease Diagnostic Kit in August 2024. Developed using their unique EpitoGen platform, this ELISA-based assay includes approximately 120 unique Borrelia epitopes, ensuring high accuracy and sensitivity. It is specifically designed for research use (RUO) and offers early, strain-specific detection. Furthermore, it can be tailored to suit a variety of lab applications. With its intended use for research and diagnostic laboratories, it promises to augment detection precision and provide more comprehensive understanding of Lyme disease.

What Are The Most Active Companies In The Lyme Disease Testing Market Today?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Everlywell, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Novatein Biosciences, Lyme Diagnostics Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Regional Markets Are Attracting The Most Investment In Lyme Disease Testing?

North America was the largest region in the lyme disease testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25817&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model